Botanical species · safety record

Ballota nigra

The EFSA Compendium of Botanicals holds 8 constituent measurements for Ballota nigra. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Ballota nigra L.

8Constituent measurements
0Safety records
6Cited sources
43Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 43 licensed products naming Ballota nigra as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry

Source material stated

  • Aerial parts
  • Flower
  • Flowering leafy twigs
  • Herb top
  • Leaf
  • Leaf and flower
  • New material
  • Whole plant(s)

What the records describe

Constituents measured

  • Furan derivatives2
  • 1,8-cineole1
  • Ballonigrin1
  • Ballotetroside1
  • Diterpene ketones1
  • Phenylpropanoids1
  • Saponins1

Plant parts

  • Aerial part of plants3
  • Unspecified3
  • Leaves1
  • Live plants1

Preparations

  • Solvent extraction4
  • Essential oil1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
BallotetrosideAerial part of plantsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
Diterpene ketonesAerial part of plantsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
1,8-cineoleAerial part of plantsEssential oil2.6 PercentGC-MSNo resolvable identifier
BallonigrinLeavesSolvent extractionNuclear Magnetic Resonance (NMR)No resolvable identifier
Furan derivativesUnspecifiedUnspecifiedNo resolvable identifier
Furan derivativesLive plantsSolvent extractionNuclear Magnetic Resonance (NMR)No resolvable identifier
PhenylpropanoidsUnspecified4 PercentUnspecifiedNo resolvable identifier
SaponinsUnspecifiedUnspecifiedNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Savona, Giuseppe., Piozzi, Franco., Hanson, James R., Siverns, Michael. Structures of three new diterpenoids from Ballota species.. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1977, no. 3, p. 322-4.
  2. Seidel, V., Bailleul, F., Libot, F., Tillequin, F. A phenylpropanoid glycoside from Ballota nigra. Phytochemistry, 1997, vol. 44, no. 4, p. 691-693. DOI
  3. Toth, Eniko., Toth, Gabor., Mathe, Imre., Blunden, Gerald. Martynoside, forsythoside B, ladanein and 7a-acetoxyroyleanone from Ballota nigra L.. BIOCHEMICAL SYSTEMATICS AND ECOLOGY, 2007, vol. 35, no. 12, p. 894-897. DOI
  4. Balansard, J. Pharmacological study of Ballota foetida.. Comptes rendus des seances de la societe de biologie et de ses filiales, 1934, vol. 115, p. 1295-7.
  5. Jamzad, Mina., Rustaiyan, Abdolhossein., Jamzad, Ziba., Masoudi, Shiva. Essential Oil Composition of Salvia indica L., Thymus caucasicus Wind. Ex Ronniger subsp Grossheimii (Ronniger) Jalas. and Ballota nigra L. Three Labiatae Species from Iran . Journal of essential oil bearing plants, 2011, vol. 14, no. 1, p. 76-83.
  6. Seidel, Veronique., Bailleul, Francois., Tillequin, Francois. Terpenoids and phenolics in the genus Ballota L. (Lamiaceae).. Recent research developments in phytochemistry, 1999, vol. 3, p. 27-39.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue